A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma

OBJECTIVES: TPI 287 is a synthetic taxane derivative with structural modifications allowing for central nervous system (CNS) penetration and potential circumvention of multi-drug resistance efflux pump mechanisms. The objective of this Phase I study was to determine the maximum tolerated dose (MTD)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Melanoma Res
Autors principals: McQuade, Jennifer L., Posada, Liberty P., Lecagoonporn, Srisuda, Cain, Suzanne, Bassett, Roland L., Patel, Sapna P., Hwu, Wen-Jen, Hwu, Patrick, Davies, Michael A., Bedikian, Agop Y., Amaria, Rodabe N.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5336360/
https://ncbi.nlm.nih.gov/pubmed/27540836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000296
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars